Post-hematopoietic stem cell transplantion immune-mediated cytopenias

Immunotherapy
Panagiotis D TsirigotisMichael-Yechiel Shapira

Abstract

Immune-mediated cytopenias after allogeneic stem cell transplantation can be categorized as either alloimmune when host or donor immunity reacts against donor or host elements, respectively, or autoimmune when donor immunity reacts against donor hematopoietic tissue, owing to poorly understood mechanisms that result in severe impairment of central and peripheral tolerance. Immune cytopenias are manifested as monolineage or more rarely as bilineage cytopenias, and are usually mediated through humoral immune mechanisms. On the contrary, immune-mediated pancytopenia is a rare event with only few cases reported in the literature. The exact pathogenesis of immune pancytopenia is not well known although it is possible that cellular immunity may play a significant role. The importance of these syndromes lies in the fact that they can cause severe morbidity and mortality. Differential diagnosis from other causes of post-transplant pancytopenia is of extreme value because these disorders can respond to various treatment modalities.

References

Mar 7, 1991·The New England Journal of Medicine·J L Ferrara, H J Deeg
Jun 1, 1991·British Journal of Haematology·A BasheyJ M Hows
Oct 1, 1993·Current Opinion in Immunology·R Parkman
Nov 25, 1998·Bone Marrow Transplantation·Y Sherer, Y Shoenfeld
Nov 11, 1999·British Journal of Haematology·R E JohnstonP D Griffiths
Nov 11, 1999·European Journal of Immunology·K GrigoriadouF A Lemonnier
Jul 20, 2002·Bone Marrow Transplantation·G StussiJ D Seebach
Jun 14, 2003·Leukemia Research·Panagiotis TsirigotisPanos Apostolidis
Dec 10, 2003·Journal of Pediatric Hematology/oncology·Paul WoodardRupert Handgretinger
Oct 27, 2004·Bone Marrow Transplantation·P BaderT Klingebiel
Jan 18, 2006·Seminars in Hematology·Petra Hoffmann, Matthias Edinger
Aug 29, 2013·The Neurohospitalist·Amy A PruittMyrna R Rosenfeld

❮ Previous
Next ❯

Citations

Oct 26, 2011·Transfusion·Fermin M Sánchez-GuijoMaria-Consuelo del Cañizo
May 23, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yan LinJianmin Wang
Apr 21, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Zhuoyan LiBipin N Savani

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
bone
PCR

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.